Pfizer (NYSE:PFE) Releases FY 2026 Earnings Guidance

06 Feb 2026, 13:21 by Amy Steele · The Cerbat Gem

Pfizer (NYSE:PFE – Get Free Report) updated its FY 2026 earnings guidance on Wednesday. The company provided EPS guidance of 2.800-3.000 for the period, compared to the consensus EPS estimate of 2.970. The company issued revenue guidance of $59.5 billion-$62.5 billion, compared to the consensus revenue estimate of $60.9 billion.

Pfizer Price Performance

Pfizer stock traded up $0.63 during mid-day trading on Friday, hitting $27.12. The company’s stock had a trading volume of 24,670,169 shares, compared to its average volume of 52,494,453. The company has a quick ratio of 0.97, a current ratio of 1.28 and a debt-to-equity ratio of 0.62. Pfizer has a twelve month low of $20.92 and a twelve month high of $27.69. The stock has a market capitalization of $154.17 billion, a P/E ratio of 19.95 and a beta of 0.47. The stock’s fifty day moving average price is $25.58 and its two-hundred day moving average price is $25.08.

Pfizer (NYSE:PFE – Get Free Report) last posted its quarterly earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share for the quarter, topping analysts’ consensus estimates of $0.57 by $0.09. The business had revenue of $17.56 billion for the quarter, compared to the consensus estimate of $16.93 billion. Pfizer had a net margin of 12.42% and a return on equity of 20.25%. Pfizer’s revenue for the quarter was down 1.2% compared to the same quarter last year. During the same period in the prior year, the business posted $0.63 earnings per share. Research analysts forecast that Pfizer will post 2.95 earnings per share for the current year.

Pfizer Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 6th. Shareholders of record on Friday, January 23rd will be issued a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 6.3%. The ex-dividend date of this dividend is Friday, January 23rd. Pfizer’s payout ratio is presently 126.47%.

Analysts Set New Price Targets

PFE has been the topic of a number of research analyst reports. Scotiabank assumed coverage on Pfizer in a research report on Thursday, November 13th. They set a “sector outperform” rating and a $30.00 price target on the stock. Morgan Stanley lowered their price objective on shares of Pfizer from $32.00 to $28.00 and set an “equal weight” rating for the company in a research report on Friday, December 12th. Cantor Fitzgerald reiterated a “neutral” rating and set a $27.00 target price on shares of Pfizer in a report on Wednesday. Weiss Ratings reissued a “hold (c-)” rating on shares of Pfizer in a research report on Thursday, January 22nd. Finally, Wolfe Research set a $24.00 price target on shares of Pfizer and gave the company an “underperform” rating in a research note on Wednesday, December 17th. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, twelve have given a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Hold” and an average target price of $28.06.

Read Our Latest Stock Analysis on Pfizer

More Pfizer News

Here are the key news stories impacting Pfizer this week:

Positive Sentiment: Q4 beat: Pfizer reported stronger-than-expected Q4 results (revenue $17.56B; adjusted EPS beat) that helped lift sentiment and confirm near-term cash flow strength. Pfizer (NYSE:PFE) Stock Price Up 4.1% Following Better-Than-Expected Earnings
Positive Sentiment: Strong obesity program momentum: Positive Phase 2b VESPER‑3 topline results for Pfizer’s GLP‑1 candidate showed up to ~12.3% placebo‑adjusted weight loss at 28 weeks — a result that supports Pfizer’s ambition to capture share in the fast‑growing weight‑loss market and helps the growth outlook beyond legacy COVID revenues. Pfizer (PFE) Announces Positive Phase 2b Results for Obesity Drug Showing 12.30% Weight Loss
Positive Sentiment: Regulatory catalyst: The FDA granted Priority Review for an sBLA for HYMPAVZI® (marstacimab) to broaden hemophilia indications — a near‑term regulatory milestone that could expand revenue for an approved product. FDA Grants Priority Review for HYMPAVZI® (marstacimab) sBLA
Positive Sentiment: Pipeline progress — obesity mid‑stage readout: Pfizer completed a mid‑stage trial for PF‑07976016 (another obesity candidate), adding redundancy and optionality to its weight‑loss program and reducing binary risk tied to a single molecule. Pfizer Completes Mid-Stage Trial of New Obesity Drug Candidate PF-07976016
Neutral Sentiment: Cost and access initiative: Pfizer launched a TrumpRx cost‑savings program to lower patient prices on a selection of medicines — positive for PR and patient access but with unclear near‑term P&L impact. Pfizer Launches Cost-Savings Program on TrumpRx
Neutral Sentiment: Analyst commentary/market framing: Several pieces present a cautious‑upside or bull‑case view emphasizing AI, oncology and multiple pipeline shots on goal — supportive of a longer‑term re‑rating but not immediate price drivers by themselves. Pfizer Stock Forecast: Trending Analysts See Cautious Upside
Negative Sentiment: Clinical setback: Pfizer paused an early‑stage trial of PF‑07258669 in older adults — a delay that raises near‑term uncertainty around that program and reminds investors of binary clinical risks in R&D. Pfizer Halts Early-Stage Trial for PF-07258669 in Older Adults

Institutional Investors Weigh In On Pfizer

A number of hedge funds and other institutional investors have recently modified their holdings of the company. State Street Corp lifted its position in shares of Pfizer by 0.9% in the 3rd quarter. State Street Corp now owns 299,087,408 shares of the biopharmaceutical company’s stock worth $7,620,747,000 after purchasing an additional 2,786,098 shares during the period. Northern Trust Corp lifted its stake in shares of Pfizer by 1.4% in the 3rd quarter. Northern Trust Corp now owns 64,019,807 shares of the biopharmaceutical company’s stock valued at $1,631,225,000 after purchasing an additional 869,175 shares during the period. Amundi boosted its position in shares of Pfizer by 10.8% during the 3rd quarter. Amundi now owns 41,490,929 shares of the biopharmaceutical company’s stock valued at $1,096,380,000 after purchasing an additional 4,043,413 shares in the last quarter. Invesco Ltd. increased its holdings in Pfizer by 3.7% in the third quarter. Invesco Ltd. now owns 30,335,842 shares of the biopharmaceutical company’s stock worth $772,957,000 after purchasing an additional 1,085,701 shares in the last quarter. Finally, Unisphere Establishment boosted its holdings in shares of Pfizer by 13.8% during the 3rd quarter. Unisphere Establishment now owns 14,400,000 shares of the biopharmaceutical company’s stock worth $366,912,000 after buying an additional 1,750,000 shares in the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

About Pfizer

(Get Free Report)

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.